Tweet
Bigtex posted this on wcbb.
Paul D. Thompson, MD; Eileen M. Cullinane; Stanley P. Sady, PhD; et al. Contrasting Effects of Testosterone and Stanozolol on Serum Lipoprotein Levels. JAMA. 1989;261(8):1165-1168.
Abstract
Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL3 subfraction. Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy ( + 25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-α-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations.
So Winstrol reduced HDL by 33% and increased LDL by 29%
Anavar or Oxandrolone is also well-known for suppressing HDL cholesterol, as well as increasing LDL cholesterol. Standard male therapeutic doses can increase LDL cholesterol by as much as 21% and decrease HDL cholesterol as much as 53%.
Winstrol is actually a little better in HLD reduction but Anavar is lightly better at not increasing LDL.
All changes were reversed following termination of the drugs.
Hara T , Miller JP , Gotto AM Jr , Patsch JR. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins. Artery, 1981, 9(5):328-341.
Abstract
The effects of stanozolol, 17-methyl-2H-5α-androst-2-eno[3,2-c]pyrazol-17β-ol, on lipoprotein levels were assessed in a short-term (6 wk) prospective study of 10 normolipidemic, postmenopausal, osteoporotic women. While total cholesterol and triglyceride levels remained constant, equal and offsetting responses were seen in low density lipoprotein (LDL) cholesterol (+30.9 ± 28.1 mg/dl [mean ± S.D.], p < 0.01, a 21% increase) and high density lipoprotein (HDL) cholesterol (−32.5 ± 11.9 mg/dl [mean ± S.D.], p < 0.001, a 53% decline). Hence the LDLHDL ratio increased dramatically, from 2.5 ± 0.7 to 6.8 ± 2.5. Within HDL, stanozolol was associated with a greater decline in HDL2 (from 26.0 ± 7.4 mg/dl to 3.8 ± 1.9 mg/dl, p < 0.001, an 85% decrease) than HDL2 (which diminished from 35.7 ± 3.2 to 24.1 ± 5.8 mg/dl, p < 0.001, a 35% decrease). The major HDL apolipoproteins also declined (A-I by a mean of 41% and A-II by 24%, both p < 0.001). Postheparin hepatic triglyceride lipase increased (off treatment 74 ± 42 nmole free fatty acid min−1 mole−1, on treatment 242 ± 110, n = 6, p = 0.06). All changes were reversed by 5 wk following termination of the drug. These lipoprotein changes suggest caution in the long term prescription of stanozolol, particularly in those without overriding clinical indications for its use.
As far as liver hepatotoxicity, Anavar, unlike other orally administered C17α-alkylated AASs, the novel chemical configuration of oxandrolone confers a resistance to liver metabolism as well as marked anabolic activity. In addition, oxandrolone appears not to exhibit the serious hepatotoxic effects (jaundice, cholestatic hepatitis, peliosis hepatis, hyperplasias and neoplasms) attributed to the C17α-alkylated AASs. Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level. Winstrol, on the other hand may be more liver toxic.
As far as joint injuries, I have seen studies that said Winstrol may in fact strengthen joints and tendons. Though many anecdotally claim otherwise.
Because of Anavar is slightly safer at lower doses and has been show to help oxidize fat, I prefer Anavar over Winstrol.
Paul D. Thompson, MD; Eileen M. Cullinane; Stanley P. Sady, PhD; et al. Contrasting Effects of Testosterone and Stanozolol on Serum Lipoprotein Levels. JAMA. 1989;261(8):1165-1168.
Abstract
Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL3 subfraction. Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy ( + 25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-α-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations.
So Winstrol reduced HDL by 33% and increased LDL by 29%
Anavar or Oxandrolone is also well-known for suppressing HDL cholesterol, as well as increasing LDL cholesterol. Standard male therapeutic doses can increase LDL cholesterol by as much as 21% and decrease HDL cholesterol as much as 53%.
Winstrol is actually a little better in HLD reduction but Anavar is lightly better at not increasing LDL.
All changes were reversed following termination of the drugs.
Hara T , Miller JP , Gotto AM Jr , Patsch JR. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins. Artery, 1981, 9(5):328-341.
Abstract
The effects of stanozolol, 17-methyl-2H-5α-androst-2-eno[3,2-c]pyrazol-17β-ol, on lipoprotein levels were assessed in a short-term (6 wk) prospective study of 10 normolipidemic, postmenopausal, osteoporotic women. While total cholesterol and triglyceride levels remained constant, equal and offsetting responses were seen in low density lipoprotein (LDL) cholesterol (+30.9 ± 28.1 mg/dl [mean ± S.D.], p < 0.01, a 21% increase) and high density lipoprotein (HDL) cholesterol (−32.5 ± 11.9 mg/dl [mean ± S.D.], p < 0.001, a 53% decline). Hence the LDLHDL ratio increased dramatically, from 2.5 ± 0.7 to 6.8 ± 2.5. Within HDL, stanozolol was associated with a greater decline in HDL2 (from 26.0 ± 7.4 mg/dl to 3.8 ± 1.9 mg/dl, p < 0.001, an 85% decrease) than HDL2 (which diminished from 35.7 ± 3.2 to 24.1 ± 5.8 mg/dl, p < 0.001, a 35% decrease). The major HDL apolipoproteins also declined (A-I by a mean of 41% and A-II by 24%, both p < 0.001). Postheparin hepatic triglyceride lipase increased (off treatment 74 ± 42 nmole free fatty acid min−1 mole−1, on treatment 242 ± 110, n = 6, p = 0.06). All changes were reversed by 5 wk following termination of the drug. These lipoprotein changes suggest caution in the long term prescription of stanozolol, particularly in those without overriding clinical indications for its use.
As far as liver hepatotoxicity, Anavar, unlike other orally administered C17α-alkylated AASs, the novel chemical configuration of oxandrolone confers a resistance to liver metabolism as well as marked anabolic activity. In addition, oxandrolone appears not to exhibit the serious hepatotoxic effects (jaundice, cholestatic hepatitis, peliosis hepatis, hyperplasias and neoplasms) attributed to the C17α-alkylated AASs. Oxandrolone is reported to be generally well tolerated and the most commonly documented adverse effects are transient elevations in transaminase levels and reductions in high density lipoprotein cholesterol level. Winstrol, on the other hand may be more liver toxic.
As far as joint injuries, I have seen studies that said Winstrol may in fact strengthen joints and tendons. Though many anecdotally claim otherwise.
Because of Anavar is slightly safer at lower doses and has been show to help oxidize fat, I prefer Anavar over Winstrol.
Comment